Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.

Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.

Recent Highlights

-- This week at the 39th Annual Meeting on Women's Cancer hosted by the Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented positive interim results from the company's ongoing Phase 2 clinical trial of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent

SNS-595 at a dose of 48 mg/m2 administered once every three weeks,

with the majority of these women having been enrolled since October.

Forty-five women have sufficient follow up to yield useful safety

results and 35 are evaluable for best response using GOG-RECIST

criteria.

-- In this trial, SNS-595 has demonstrated disease control (defined as

stable disease, partial response or complete response), with 31 of

35 of evaluable patients having best responses of stable disease or

better. Of
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 Dr. Ingrid Warmuth and Anamaria ... NJ, are proud to announce an Open House at their ... on Saturday, June 8th from 10 AM to 2 PM. ... MHS, PA-C and staff will be on hand to talk ... aesthetic treatments, and provide complimentary cosmetic consultations. There will also ...
(Date:5/24/2013)... 2013 In a sneak preview ... will present technologies with applications in multiple and ... SPIE Optics and Photonics symposium in San ... the international society for optics and photonics , ... sciences and technology meeting in North America, with ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Bed bug cases ... protect themselves from the looming higher risk of becoming the ... a new bed bug guideline. In the guide, the company ... and avoiding them while traveling. , According to ... an increase of bed bug infestation during summer: the warm ...
(Date:5/24/2013)... and TEL AVIV, Israel , ... or the "Company") (NYSE MKT: NSPR), a leader in embolic ... the Company,s President and Chief Executive Officer, and ... participate in the Benchmark Company, LLC One-on-One Investor Conference on ... Wisconsin Ave., Milwaukee, WI. ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4
... and Products Offset Patent Expirations, SAN FRANCISCO, ... of major neuropathic pain (NP) conditions is currently ... a report released today by,WWMR, Inc. Growth over ... by the,successful launch of Lyrica (pregabalin) for diabetic ...
... in Pharmaceutical Thin Film,Technology -, WARREN, N.J., ... specializing in quick dissolving thin film pharmaceutical products,today ... No. 7,425,292 from the,United States Patent and Trademark ... to issue on September 16, 2008, relates,to the ...
... 11 BioTrends Research Group, Inc. is,pleased to announce ... report in a series conducted with Anemia Managers. It ... by 150 Anemia Managers,-- 100 working with dialysis patients ... patients, and qualitative interviews with a,subset of 25 respondents. ...
Cached Biology Technology:US Neuropathic Pain Market Value Doubles to $5 Billion by 2018 2US Neuropathic Pain Market Value Doubles to $5 Billion by 2018 3MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 2MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 3New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices 2New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices 3
(Date:5/24/2013)... complex systems like ecosystems can get messy, especially when ... unknowns like climate change. , In a new ... Proceedings of the National Academy of Sciences , researchers ... fundamental assumption at the very heart of a popular ... model how climate changes may impact biodiversity, researchers like ...
(Date:5/24/2013)... 2013 A frequently expressed concern in the ongoing public ... vegetables, especially those that are nutrient dense. A ... Beans Provide Most Nutrients Per Penny," published in the ... one of the best nutritional values in the produce ... penny than most other raw vegetables and delivering one ...
(Date:5/24/2013)... and fastest growing open-access publishers, today announces the launch ... , A broad scope journal covering all specialties, ... interactive web platform for the research community to publish ... real-time and interactive peer-review enables fast, fair and constructive ... average of three months from submission to final decision ...
Breaking Biology News(10 mins):Understanding the past and predicting the future by looking across space and time 2New research shows that potatoes provide one of the best nutritional values per penny 2Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3
... Des Moines, Iowa March 1, 2010 You ... three language-competent bonobos living at Great Ape Trust, than you ... day tell scientists more about the effect of culture on ... is a universal language, an alternative to spoken words to ...
... years on Down,s syndrome has focused on the DYRK1A ... the neurones, according to Mr Garikoitz Azkona. In his ... Down,s syndrome: the role of DYRK1A , Mr Azkona ... behind the problem that persons with Down,s syndrome have ...
... well known for keeping us healthy as it is for ... new research report appearing in the March 2010 print issue ... explain how they developed a genetically modified strain of tobacco ... scientifically known as microcystin-LR (MC-LR), which makes water unsafe for ...
Cached Biology News:If bonobo Kanzi can point as humans do, what other similarities can rearing reveal? 2If bonobo Kanzi can point as humans do, what other similarities can rearing reveal? 3DYRK1A gene may be 1 of most influential factors in Down syndrome 2
Request Info...
Request Info...
Request Info...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
Biology Products: